



08 DECEMBER 2021

eTheRNA immunotherapies conference attendance from December 2021 to March 2022

Niel (Belgium)

eTheRNA immunotherapies NV ('eTheRNA'), a private clinical-stage biotechnology company developing mRNA-based immunotherapies for the treatment of cancer and infectious diseases, will be attending the following conferences from December 2021 to March 2022:

[BioFIT Digital](#)

7-9 December 2021

[Tim Van Assche](#), VP of Business Development and Alliance will be in attendance.

[ESMO Immuno-Oncology Online Congress](#)

8-11 December 2021

[Marina Cools](#), VP of Clinical Development will be in attendance.

[Kempen Life Sciences Crossover Conference](#)

6 January 2022

[Steven Powell](#), Chief Executive Officer, and Mathieu Lane, Chief Financial Officer of eTheRNA Inc., will be in attendance.

[Biotech Showcase](#)

10-12 January 2022

[Steven Powell](#), Chief Executive Officer, and Mathieu Lane, Chief Financial Officer of eTheRNA Inc., will be in attendance.

[mRNA-Based Therapeutic Summit Europe](#)

25-27 January 2022

[Volker Germaschewski](#), Vice President of Research and Development, will be speaking about, "Engineering the Future of mRNA Therapies," on Wednesday 26 January 2022 from 1:00-1:15 pm CET.

[RNA Therapeutics Conference](#)

9-10 February 2022

[Volker Germaschewski](#), Vice President of Research and Development, will be speaking about, "Engineering the Future of mRNA Therapies," on Thursday 10 February 2022 from 12:40-1:00 pm CET.

[FlandersBio — Joint Economic Mission to the United Kingdom](#)

6-10 March 2022

[Volker Germaschewski](#), Vice President of Research and Development, and [Tim Van Assche](#), Director of Business Development and Alliance Management will be in attendance.



About eTheRNA immunotherapies

eTheRNA immunotherapies NV is developing immunotherapy and vaccine products for the treatment of cancer and infectious disease from its mRNA chemistry, antigen identification, lipid chemistry and delivery and process engineering platforms. The company is headquartered in Belgium and was established in 2013. Its founding shareholders include Progress Pharma and VUB. eTheRNA is supported by an international group of specialised investors; BNP Fortis Private Equity, Boehringer Ingelheim Venture Funds, Everjoy Fortune PTE. LTD, Grand Decade Development Limited, Fund+, LSP, Novalis Lifesciences, Omega Funds, PMV and Ying Zhou Enterprise Management Company Limited who share the Company's ambition to build a world-leading company in the RNA field. To date, the Company has raised €63 million of venture funding. Further details relating to eTheRNA's R&D pipeline can be found at <https://www.etherna.be/immunotherapies-rd-pipeline/>.

Contact Information

media@etherna.be